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                                                      ABSTRACT 
 
Regulation of Cloned Cardiac Channels. (August 2005) 
 
Bharathi Balasubramanian, B.E., Madras University 
 
Co-Chairs of Advisory Committee: Dr. Charles S. Lessard 
                                                          Dr. Michael J. Davis 
 
 
         Activation of a5ß1 integrin potentiates L-type calcium current in vascular smooth 
muscle, which is partly mediated by tyrosine phoshorylation of the a1c channel subunit. 
Expressed rabbit VSM and neuronal isoforms are also potentiated by a5ß1 integrin 
activation and require dual phosphorylation of a1c by PKA and c-Src. To explore 
common mechanisms of regulation by a5ß1 integrin, whole cell patch clamp experiments 
were used to investigate the effects of a5ß1 integrin antibody on expressed cardiac 
calcium channels. In HEK cells transfected with a1c, ß2a and a2-d1 subunits alone, 
currents increased 1.8 – 2.0 fold on application of a5ß1 antibody. The potentiation was 
almost completely abolished on the application of PKI, a highly specific Protein Kinase 
A (PKA) inhibitor. The expressed currents increased 2.0 – 2.2 fold on application of 
PKA activator 8-Br-cAMP, and abolished by PKI. Our results suggest that regulation of 
L-type calcium channels by a5ß1 integrin is a general mechanism shared by VSM, 
neuronal and cardiac channels. However, in the cardiac isoform, only PKA 
phosphorylation is involved. 
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         CHAPTER I 
INTRODUCTION 
 
The focus of this thesis is to test whether the cardiac L-type calcium channel is 
potentiated by activation of a5ß1 integrin and whether the potentiation depends on 
phosphorylation of a channel serine residue by Protein Kinase A (PKA) and/or a tyrosine 
residue by c-Src. Studies on the regulation of the smooth muscle and neuronal L-type 
calcium channel by a5ß1 integrin were conducted previously in our lab and their 
mechanism of regulation has been established. Investigating the regulation of cardiac L-
type calcium currents would aid in assessing common regulatory pathways for this 
channel between the three muscle types, viz. cardiac, neuronal and smooth muscle, 
based on their structural homology and thus help in understanding how they contribute 
to the unique behavior of the respective muscle types. 
 
A. BACKGROUND 
Calcium channels are found in every mammalian cell. By controlling the flow of 
calcium ions into the cytoplasm, calcium channels can regulate a host of calcium-
dependent intracellular events (1). 
Voltage dependent calcium channels (VDCC) are a family of calcium channels  
_______________ 
This thesis follows the style and format of The Journal of Biological Chemistry. 
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found in excitable cells such as nerve and muscle. VDCC activate when the membrane is  
depolarized and usually require a strong depolarization for significant opening. The 
probability of opening is steeply voltage dependent and is delayed relative to the gating 
of sodium channels that are also typically found in excitable cells. Compared to sodium 
currents, the calcium currents thus produced are quite minimal (1). Even when 
maximally activated, whole-cell VDCC current (ICa) rarely exceeds 100 µA/cm2. Since 
ICa is generally small but slowly decaying, pure Ca2+ action potentials have a low rate of 
rise, a low conduction velocity, and a long duration (1). 
Based on physiological and pharmacological criteria there are multiple types of 
VDCC present in various cell types, viz. P, Q, R, N, T and L.  P and Q type calcium 
channels are found in nerve terminals and dendrites; their primary functions are 
neurotransmitter release and producing dendritic Ca2+ transients. R-type channels are 
located in cell bodies, dendrites and nerve terminals and are primarily responsible for 
generating Ca2+ dependent action potentials. T-type channels are found in cardiac 
muscle, skeletal muscle and neurons and are thought to be involved in pacemaker 
activity. The main focus of this thesis is on the L-type calcium channels which are 
located in skeletal muscle, cardiac muscle, endocrine cells, neurons and smooth muscle. 
L-type currents are distinguished by high voltage of activation, a relatively large single-
channel conductance, slow voltage-dependent inactivation, marked regulation by 
intracellular kinases and specific inhibition by Ca2+ antagonist drugs including 
dihydropyridines, phenylalkylamines and benzodiazepines. Verapamil, D-600 and 
nifedipine are commonly used blockers of L-type calcium current (1). 
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In a resting mammalian cell, the cytoplasmic calcium level is held very low, 
typically within the range 10 – 200 nM (1). Whenever a calcium channel opens, Ca2+ 
ions enter the cytoplasm, raising the intracellular Ca2+ concentration transiently until 
buffering or pumping mechanisms tie up or remove the extra Ca2+. An increase in 
intracellular calcium secondary to Ca2+ entry results in the complexing of Ca2+ with 
calmodulin (CaM) and other Ca2+ binding proteins. In muscle, Ca2+ – CaM activates 
Ca2+ – dependent regulatory contractile proteins, for example troponin in striated muscle 
or myosin light chain kinase in smooth muscle. The result is shortening of the contractile 
apparatus and development of active tension. Secretion from nerve terminals and from 
different types of excitable cells requires extracellular Ca2+. Katz and Miledi have 
proposed that the opening of voltage-gated calcium channels in the presynaptic potential  
allow a burst of calcium ions into the cell (1). These calcium ions then bind with 
intracellular calcium sensors that act in unison to initiate vesicle fusion and cause 
exocytosis of neurotransmitter. Intracellular calcium ions also have an important role to 
play in gating of channels and such modulation has been reported in several Ca2+, K+ and 
Cl- channels. These channels are known to have intracellular binding sites for calcium or 
calmodulin and are known to have a direct effect on gating (1). 
Based on their tissue-specific expression, L-type calcium channels can be 
classified as neuronal, smooth muscle, skeletal or cardiac channels. Neuronal, smooth 
muscle and cardiac channels are of one class (a1C); skeletal muscle channels are of a 
separate class (a1D). The main emphasis of this thesis is on the cardiac calcium channel 
subclass, a1C-a. In all four tissues, L-type channels are regulated by a number of 
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hormones, neurotransmitters and intracellular kinases, thereby allowing the cells to have 
exquisite control of extracellular calcium entry. The intracellular kinases whose role in 
the regulation of L – type channels are of primary interest in this thesis are Protein 
Kinase A (PKA) and pp60c-Src.  
In describing the rationale for studying the regulation of L – type currents by 
these kinases, a discussion of the molecular structure and properties of Ca2+ channels is 
appropriate. The primary structure of the Ca2+ channel (Fig 1) consists of the pore-
forming a1 subunit, composed of amino acid sequences organized in four repeating 
domains (I to IV), each of which contains six transmembrane segments (S1 to S6) and an 
intracellular, membrane-associated loop between transmembrane segments S5 and S6 
(2). The S4 segment of the  
 
 
                       
Fig 1. Structure of L-type calcium channel (Keef et al., Am J Physiol 281:C1743-
C1756, 2001). 
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a1 subunit serves as the voltage sensor for activation. The S5 and S6 segments and the 5-
6 loop constitute the pore. S6 is the receptor site for L-type specific Ca2+ antagonists. An 
intracellular ß - subunit contains a domain that interacts with the I – II loop of the a1 
subunit. The functions of the ß subunit are plasma membrane targeting and modulation 
of channel gating. The channel also consists of a d subunit, which is a membrane protein 
and an a2 subunit, which is an extracellular glycosylated protein. The roles of the a2 – d 
subunits are less understood but both subunits have been identified to play a role in the 
modulation of gating and membrane targeting (3). 
 
B. REGULATION BY PKA 
Protein Kinase A is widely expressed in cardiac and smooth muscle (4). The 
basic structure of PKA consists of two catalytic subunits bound to a regulatory subunit. 
A large number of G-protein coupled receptors in the heart and blood vessels are known 
to regulate the L-type calcium channel and other cellular proteins through the 
cAMP/PKA pathway (5). These receptors are coupled to either Gs, which stimulates, or 
Gi, which inhibits adenyl cyclase (AC). An increase in AC activity produces an increase 
in cellular cAMP which in turn binds to cAMP-dependent regulatory PKA subunits 
leading to phosphorylation of substrates on specific serine and/or threonine residues (6). 
Evidence for the regulation of L type calcium channels by PKA has been provided by 
electrophysiological studies performed in multiple laboratories. Agonists of ß 
Adrenergic Receptor (ßAR) signaling, predominantly ß1AR, produce an increase in ICa 
involving the cAMP/PKA pathway (3). In cardiac muscle, PKA phosphorylates a 
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number of intracellular proteins, promoting enhanced speed of contraction and 
relaxations.  
Evidence for direct phosphorylation of L-type channels by PKA has come from 
biochemical studies. Experiments where the full- length form of a1C was truncated at its 
C-terminus showed that only the full- length form was phosphorylated by PKA; thus, the 
PKA phosphorylation site was situated in the truncated portion. Serine 1928 in the a1C 
C-terminus has been identified as the phosphorylation site (6). These results has been 
further supported by experiments where mutation of Serine 1928 to Alanine, prevented 
phosphorylation of channel by PKA (5). It has also been shown that the b  calcium 
channel subunit is responsible for a smaller fraction of current potentiation in the same 
cells (7). 
 
C. REGULATION BY PKC 
Multiple Gq protein-coupled receptors including endothelin (ET), a1 adrenergic 
and angiotensin II receptors, trigger events leading to the activation of PKC (6). The 
regulation of L-type calcium channels by PKC is controversial. Direct activators of PKC 
produce biphasic effects on ICa in certain preparations. These diverse effects may be due 
in part to the existence of at least 11 different isoforms of PKC which are divided into 
three groups:  
1) classic or conventional PKCs (cPKC) that are activated by diacyl glycerol and are 
calcium sensitive; 
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 2) novel or new PKCs (nPKC) that are activated by diacylglycerol or phorbol ester but 
are calcium insensitive; 
3) atypical PKCs (aPKC) that are not activated by diacylglycerol or phorbol ester and 
are calcium insensitive (6). 
  In the cardiac muscle cell, PKC phosphorylates a number of proteins which 
contribute to excitation and contraction. Amongst these is the L-type calcium channel in 
which both the a1 and the ß2 subunits are phosphorylated by PKC in vitro. Experimental 
studies have shown that the first 46 amino acids at the NH2 terminal end of the cardiac 
a1 subunit inhibit channel activity (8, 5). Removal of these residues results in 
enhancement of channel activity by PKC. Also, there is evidence that different isoforms 
of PKC have different effects, with cPKCs producing inhibition of current and nPKCs 
enhancing current. Further studies show that for channels expressed in TSA-201 cells, 
inhibition of channel activity by PKC is through phosphorylation of Threonine 27 and 
Threonine 31 at the NH2 terminus end of the a1 subunit (9).     
. 
D. REGULATION BY PKG 
PKG catalyzes the phosphorylation of a number of intracellular proteins that 
modulate muscle contraction. There are two main types of PKG, Type I and Type II. The 
cardiac muscle cell contains PKG Type I (9). There is controversy in the role of the 
cGMP/PKG pathway in regulation of myocardial function, with some studies reporting 
cGMP/PKG mediated inhibition of L-type calcium channels, while others report the 
opposite effect especially when the cAMP levels are high. But in most cases where 
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potentiation was observed, the mechanism was not through the direct phosphorylation of 
PKG, but was indirect through PKA activation. Three different mechanisms have been 
suggested for cGMP-induced inhibition of L-type calcium channels, one of which is 
through the direct phosphorylation of the channel by PKG on Serine 533 (10). 
The previous discussion was based on results obtained from experiments that 
investigated each pathway individually without the contribution of other pathways. In 
real physiological systems, the channel is regulated by a complex mixture of cellular 
signals and a thorough understanding of the various interactions between signaling 
cascades is absolutely necessary to obtain a complete picture of how the channel is 
regulated. 
 
E. REGULATION OF CALCIUM CHANNELS BY TYROSINE KINASES 
Protein Tyrosine Kinases (PTK) were discovered as products of oncogenes from 
transforming retroviruses and are responsible for transducing key extracellular signals 
that mediate events such as proliferation, cytoskeletal rearrangement and coordination of 
physiological responses (11).  PTKs are of two types, receptor and non-receptor tyrosine 
kinases. Several studies have shown that PTKs regulate VDCC, including pp60c-Src 
(11).  In smooth muscle myocytes, PTK inhibitors produce a reduction in Ca2+ current, 
whereas protein tyrosine phosphatases (PTP) inhibition increases current (12). The 
intracellular application of constitutively active Src kinases increases ICa. c-Src-activating 
peptide also has a similar effect, whereas a monoclonal antibody for c-Src inhibits ICa 
(12, 13).  
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G. INTEGRINS-FUNCTIONS AND PHYSIOLOGICAL RELEVANCE 
  Integrins are heterodimeric transmembrane proteins that play a very important 
functional role in connecting the extracellular matrix (ECM) to the cell body or the 
cytoskeleton (12). Integrins are also known to regulate the L-type calcium channel. Each 
integrin is composed of a single a and ß subunit. Different combinations of 18a and 8 ß 
subunits result in the formation of more than 24 integrin family dimers (13). The ligand 
specificity of the integrin is determined by the combination of a and ß subunits, but 
many of these tend to overlap. Under these circumstances, the amount of integrin 
expression/activation pattern and the availability of the ligand specifies functional 
interactions taking place in vivo. The integrin of interest in this thesis is the a5ß1 integrin. 
The ECM ligand for this integrin is fibronectin (14). 
 Physiologically, integrins play an important role in cell-cell adhesion, cell-ECM 
adhesion, wound healing, cell proliferation, differentiation, migration and death (15). 
Integrins are particularly important in cardiac development (16). Integrins are the most 
important receptors in the ECM and hence their appropriate expression and functioning 
is indispensable for normal cardiac activity (17, 18). They are also known to play an 
important role in apotosis, by influencing signaling pathways and thereby either causing 
survival or death of the cell by its interaction with the ECM (19). The a5ß1 integrin, 
along with its ECM ligand fibronectin, also helps in wound healing (20). 
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F. MECHANISMS OF INTEGRIN REGULATION 
Recent studies (21, 23) show that the L-type calcium channels in neurons and 
blood vessels are regulated by the a5ß1 integrin through serine and tyrosine dependent 
pathways.  Activation of a5ß1 integrin increases L-type calcium currents (21). In 
vascular smooth muscle, integrin-mediated regulation of the L-type channel occurs 
through multiple intracellular pathways. The inhibition of c-Src or its upstream, integrin-
associated partner Focal Adhesion Kinase (FAK) with intracellular antibodies inhibits 
potentiation of current following a5ß1 integrin activation (21).  Application of antibodies 
to two integrin associated protein targets, paxillin and vinculin, also block regulation by 
a5ß1. The latter effect may be due to the role of these proteins in acting as a scaffold on 
which various regulatory proteins associate with PTKs. The a5ß1 integrin thus seems to 
regulate the protein tyrosine phosphorylation cascade involving c-Src and FAK.  
Platelet-derived-growth-factor (PDGF) and other growth factors increase ICa by 
stimulating tyrosine phosphorylation of multiple proteins. PDGF regulation of current is 
inhibited by antibodies to FAK (24) and c-Src (24, 25). Insulin Growth Factor  (IGF-I) is 
also known to regulate L-type current in neurons through c-Src (22). 
Recently, Gui et al. (23) have shown that recombinant neuronal and smooth 
muscle cells are acutely regulated by a5ß1 integrin through a pathway primarily 
involving the a1C channel subunit. Further studies have shown that this regulation of rat 
neuronal/ vascular smooth muscle channels by a5ß1 integrin involves dual-
phosphorylation of C-terminal residues S1901 and Y2122 (using the neuronal calcium 
channel numbering scheme) which undergo direct phosphorylation in the presence PKA 
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and c-Src respectively (23). The mechanism is supported by experiments performed in 
native smooth muscle and neuronal cells in which potentiation by a5ß1 integrin was 
blocked fully by a combination of PKA inhibitor and c-Src SH2 inhibitory peptide (23). 
 
G. a1c C-TERMINUS STRUCTURAL HOMOLOGY 
There is structural homology in the C-terminus of the a1c subunit in the rat 
neuronal calcium channel (studied by Gui et al. (23)) and the rabbit cardiac channel 
which is the channel of interest for my experiments. S1901 (the PKA phosphorylation 
site), which has been identified as the site responsible for potentiation of the channel by 
a5ß1 integrin in rat neuronal cells, corresponds to S1928 in the rabbit cardiac channel C-
terminus (3). Notably, the rabbit cardiac channel lacks the critical tyrosine residue 
(corresponding to Y2122 on rat neuronal calcium channel) which has been found to 
mediate ~50% of potentiation by a5ß1 integrin in the neuronal and smooth muscle 
isoforms (3). Considering this structural homology, a primary goal of this thesis is to test 
whether the cardiac L-type calcium channel is also potentiated by a5ß1 integrin activation 
and whether the potentiation depends on a1c phosphorylation by PKA on S1928 and/or 
a tyrosine residue by c-Src. 
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     CHAPTER II 
EXPERIMENTAL MATERIALS AND METHODS 
 
A. PATCH CLAMP TECHNIQUE 
          The primary technique employed in this thesis is Patch Clamping, which is a 
widely used method to study ionic currents in single cells (26). The essence of patch 
clamp recording is the use of a fire-polished glass micropipette and suction to form a 
high resistance seal between the pipette and cell membrane, combined with a low-noise 
current-to-voltage converter amplifier. The method can be used to record single channels 
or a population of channels, the so-called Whole-Cell Recording (WCR), which is the 
most common configuration of the patch clamp technique.  
 
 Whole Cell Recording 
 WCR enables the experimenter to manipulate the internal environment of the cell 
by using a patch pipette filled with appropriate solution. The pipette is pressed onto the 
cell membrane to establish a firm seal with a resistance in the order of gigaohms. The 
pipette voltage is set at a negative voltage to mimic the normal transmembrane electrical 
gradient and positive voltage steps of few millivolts are applied to gate VDCCs. 
Appropriate compensation techniques are employed in order to cancel the transients 
caused by the capacitance between the holder and the pipette wall. The cell membrane is 
then ruptured by applying gentle suction (Fig. 2), after which the pipette solution 
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exchanges with the intracellular solution. After complete exchange of the intracellular 
solution, the currents obtained are amplified and recorded. 
                        
 
 
Fig 2. Whole-Cell patch clamp configuration (http://www.bphys.uni-
linz.ac.at/bioph/res/icg/met/patch.htm). 
  
Fabrication of Patch Pipettes 
The pipettes used in patch clamping play a very important role in the formation 
of a gigaseal. The glass geometry and the pipette tip shape determine the quality of the 
recording and the stability of the seal. A lot of attention is paid to these factors to 
achieve a good seal and stable recording. The pipette glass is chosen according to the 
type of the cell being patched. For the proposed set of experiments involving HEK 293 
cells with WCR, 8161 glass was chosen for the recording pipette. The glass was then 
cleaned and pulled using a Sutter PC-97 horizontal pipette puller. To promote the 
formation of a gigaseal and to prevent pipette tip penetration into the cell, the pipettes 
were fire-polished. Fire-polishing was accomplished by heating up a short platinum wire 
by passing D.C. current through it. The pipette was brought close to the heated wire 
while observing it under a microscope and was polished until the tip was slightly 
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rounded. Care was taken to see that the pipette tip was not blocked completely by 
polishing. The fire-polished tips had diameters of 1 – 3 µm and resistances of 3 – 5M? . 
A second pipette, called the picospritzer pipette (connected to a Parker-Hannefin 
picospritzer), was used to puff small volumes of integrin antibody or 8-Br-cAMP onto 
the cell from a distance of ~5 µm. 7052 glass was chosen for this purpose and was 
cleaned and pulled using the horizontal pipette puller. The picospritzer pipette was not 
firepolished since it did not have direct contact with the cell membrane. 
 
B. CELL CULTURE AND TRANSFECTION 
HEK 293 cells transfected with the rabbit cardiac channel were used for these 
experiments. HEK cells were used rather than native cardiac myocytes to enable channel 
mutations to be performed and their effects tested. HEK cells were a convenient cell line 
to use because they do not express endogenous VDCCs but do express a5ß1 integrin. 
HEK cells were plated at 60% density one day before transfection in 10% FBS 
DMEM. 1-1.5 ml cell suspension was diluted into 4ml fresh 10% FBS DMEM. When 
the cells were 80% confluent, transfection was performed using the lipofection technique 
in 60mm dishes. 20µL of Lipofectamine 2000 and 14µg of the plasmid cDNA encoding 
the rabbit cardiac L-type calcium channel (7µg a1c, 3.5 µg ß2a, 3.5 µg a2-d1) were 
added to the dish and the dish was placed in a 37ºC incubator with 5% CO2 for 20 hours. 
Green fluorescent Protein (GFP) 2µg/dish was also added to allow identification of  
transfected cells. The next day, the cells were split with 0.05% trypsin and 0.53mM 
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EDTA and plated on sterile coverslips in 35mM dishes. Cells were maintained at 28ºC 
with 5% CO2  for 20 hours.  
 
 C. SOLUTIONS 
The calcium currents were recorded using the whole cell method with bath 
solution containing in (mmol/L) 20 BaCl2, 124 Choline chloride, 10 Hepes and 15-D 
glucose. The pH was adjusted to 7.4 using TEA-OH. Barium was used in the bath 
solution in order to obtain sustained calcium currents and block potassium currents. The 
pipette solution contained (mmol/L): CsCl 104.5, TEA-Cl 20, EGTA 11, MgCl2 2, CaCl2 
1, Hepes 10 and GTP 0.2. The pH was adjusted to 7.2 with CsOH. Cs+ was used in order 
to further block potassium currents. 
 
D. EXPERIMENTAL SETUP 
A coverslip containing the transfected HEK 293 cells was placed in the recording 
chamber. Bath solution was perfused through the recording chamber at a flow rate of 1-
3mL/min from a switchable, gravity-fed reservoir system. The cells were observed under 
a Zeiss microscope and fluorescent cells (those expressing GFP) were chosen for patch 
clamping. The recording pipette was backfilled with pipette solution in such a way as to 
eliminate air bubble formation at the pipette tip, clamped into the pipette holder, and 
connected to the preamplifier headstage. The pipette was pressed against the membrane 
to form a gigaseal, and then suction was applied to break open the membrane. The 
holding potential was -80mV to keep the channels inactivated.  Intracellular and 
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extracellular solutions were allowed to exchange for approximately ten minutes to attain 
equilibrium. The currents were then measured using ramp (-100 to +80 mV for 180 
msec) and step voltage protocols (a series of steps from -80 to +80 mV for 300 msec 
duration at 5 second intervals). The currents were amplified using a HEKA EPC9 
amplifier under the control of Pulse Software. The resolution of currents was ~1pA. 
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                                               CHAPTER III 
 
  EXPERIMENTAL PROTOCOLS AND RESULTS 
 
 
The following experiments were designed to investigate the mechanism of 
cardiac L-type calcium channel regulation by a5ß1 integrin activation. Whole-cell patch 
clamp recordings were performed on HEK 293 cells transfected with a1C, ß2a and a2-d1 
subunits of the rabbit cardiac calcium channel.  
 
A. CARDIAC a1c POTENTIATION BY a5ß1 INTEGRIN ANTIBODY (Ab) 
  This protocol was designed to test if a5ß1 integrin activation results in 
potentiation of the cardiac L-type calcium channel and, if so, to determine the amount of 
potentiation. a5ß1 integrin is constitutively expressed by HEK cells. To activate the 
integrin, soluble a5ß1 integrin Ab (10µg/L) was applied to the cell through a picospritzer 
micropipette for 5 minutes. At this concentration, the Ab is known to cross- link and 
activate the integrin. The cell was held initially at -80 mV (Fig. 3) because at this 
potential most of the calcium channels are closed. The membrane potential was then 
stepped to 10 mV (Fig. 3) where voltage peak inward current is recorded. This procedure 
was repeated continuously for up to 20 min, allowing 10-20 between voltage steps fro 
recovery of current. During this time, application of a5ß1 integrin Ab produced  
potentiation of whole-cell calcium current. The average potentiation in the absence of 
inhibitors was ~91% above the basal current level (9 cells). The raw traces of whole cell 
current before (Control) and after application of integrin are shown in Fig. 3.  
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Fig 3. Potentiation of cardiac L-type calcium channel currents by a5ß1 
integrin. Raw current traces showing effect of a5ß1 integrin Ab (10 µg/L) on calcium 
current in HEK 293 cells transfected with a1C, ß2a and a2-d1 subunits of rabbit cardiac 
channels.  
 
 
Table 1 shows the measured control currents and potentiated currents after a5ß1 
integrin activation in 9 cells expressing cardiac L-type calcium channels. The percentage 
increase in potentiation was measured in this protocol and all subsequent protocols by 
dividing the difference between the control and the potentiated current by the control 
current and multiplying the quotient by 100. Thus, each cell was used as its own control, 
which minimizes the variability associated with substantially different channel 
expression levels from cell to cell (Table 1, first column). The average potentiation for 
50ms 
100pA 
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a5ß1 integrin Ab                             
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A
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all the 9 cells was found to be 91.1 % with a standard error of 9.5%. To test significant 
differences between the control and potentiated groups, a paired t-test with a significance 
level of 0.05 was used. The p-value was found to be 0.0004. Since p<0.05, it was 
concluded that there is significant potentiation produced by application of a5ß1 integrin. 
In cells not transfected with L-type Ca2+ channels, no voltage-gated Ca2+ currents were 
detected and a5b1 integrin activation produced no effect. 
 
Table 1. Summary data for potentiation of cardiac L-type calcium channel currents 
by a5ß1 integrin. 
Control a5ß1 integrin activation (Potentiated) % Increase in Potentiation 
(pA) (pA) above control currents
136.3 274 101.0
658 1276 93.9
170 325 91.2
185 360 94.6
338 679 100.9
545 1098 101.5
1206 1437 19.2
338 750 121.9
358 700 95.5
                                               n = 9
Average % Increase in Potentiation 91.1
Standard Error 9.5
Paired t-test comparing control currents with 0.0005
a5ß1 integrin (Potentiated) currents
Significance level a=0.05  
 
 
B. CARDIAC a1c POTENTIATION BY 8-Br-cAMP 
 8-Br-cAMP is direct, cell-permeable PKA activator known to potentiate L-type 
calcium currents through the PKA pathway as discussed in Chapter I. Given the previous 
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work by our lab that PKA is involved in potentiation of the neuronal calcium channel 
following a5ß1 integrin activation, this protocol was performed to compare the  cardiac 
a1c potentiation by a5ß1 integrin antibody with potentiation by  8-Br-cAMP. We 
hypothesized there would similar amounts of potentiation produced by the two 
compounds if integrin-mediated potentiation were mediated solely through the PKA 
pathway. 
 8-Br-cAMP (1 mM) was applied to the transfected HEK 293 cells for 5 minutes 
through a picospritzer micropipette. An increase in calcium current was observed within 
1 min upon application of 8-Br-cAMP. The average potentiation from 11 cells was 
~123%. Sample raw traces of whole cell control and potentiated currents are shown in 
Fig 4.   
 
 
 
Fig. 4. Potentiation of cardiac L-type calcium channels by application of the PKA 
activator 8-Br-cAMP. Raw current traces showing effect of 8-Br-cAMP (1 mM) in 
HEK 293 cells transfected with a1C, ß2a and a2-d1 subunits of the rabbit cardiac channel. 
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Table 2 shows the measured control currents and potentiated currents produced 
by 8-Br-cAMP in 11 cells expressing cardiac L-type calcium channels. The average 
potentiation was found to be 123% with a standard error of 14.3%. To evaluate the 
significance of differences between the control and potentiated groups, a paired t-test 
with a significance level of 0.05 was used. The p-value was found to be 0.0006. Since 
p<0.05, it was concluded that significant potentiation was produced by application of 8-
Br-cAMP. 
 
Table 2. Summary data of potentiation of cardiac L-type calcium channel currents 
by 8-Br-cAMP. 
 
         Control                8BrcAMP Potentiation % Increase in Potentiation 
(pA) (pA) above control currents
173.4 231.2 33.3
136 347 155.1
173 390 125.4
668 850 27.2
115 284 147.0
99 230 132.3
361 809 124.1
173 425 145.7
273 710 160.1
180 454 152.2
120 300 150.0
                                                 n = 11
Average % Increase in Potentiation 123.0
Standard Error 14.3
Two tailed t-tests comparing Control and p = 0.0006
8-Br-cAMP Potentiated currents (pA)
Significance level a  = 0.05  
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C. EFFECT OF PKI IN THE RECORDING PIPETTE DURING a5ß1 INTEGRIN 
Ab-MEDIATED POTENTIATION OF CURRENT 
 
  This protocol was performed to test if the potentiation produced by a5ß1 integrin  
 could be prevented by PKI, a highly selective inhibitor of PKA. The results from this 
experiment would show if the potentiation produced by a5ß1 integrin was achieved 
completely through the PKA pathway. 
PKI is a peptide and is not cell-permeable, unlike 8-Br-cAMP, and so it could not 
be applied to the cell through a picospritzer micropipette. Therefore PKI (5µg/ml) was 
mixed with the pipette solution and filled in the recording pipette.  
 
 
 
Fig. 5. Effect of the PKA phosphorylation inhibitor PKI on potentiation of cardiac 
L-type calcium channel currents by a5ß1 integrin. Raw current traces showing effect 
of PKI (5µg/ml) in the recording pipette on a5ß1 integrin potentiation in HEK 293 cells 
transfected with a1C,  ß2a and a2-d1 subunits of the rabbit cardiac channels. The small 
blips in this recording are 60 Hz noise. 
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Control currents (PKI alone) were measured and recorded before the application of a5ß1 
integrin antibody. The integrin antibody (10 µg/ml) was then applied to the cell through 
a picospritzer for 5 minutes while delivering test pulses from -80 mV to +30 mV and 
recording current. Under these conditions, the potentiation produced by a5ß1 integrin 
was only a fraction of that recorded in the absence of inhibitor. The average potentiation 
was ~6% in 7 cells. Sample recordings of control and potentiated currents are shown in 
Fig 5. 
Table 3 shows the peak Ca2+ currents for cells dialyzed with PKI alone and for 
cells dialyzed with PKI and then exposed to a5ß1 integrin AB. The average potentiation 
for 7 cells was found to be 5.9% with a standard error of 1.4%. 
 
 
 
Table 3. Summary data for effect of PKI on a5ß1 integrin potentiation of  cardiac L-
type calcium channel currents. 
 
 
PKI PKI + a5ß1 integrin Ab      % Increase in potentiation 
(pA) (pA) above basal currents
174 193 9.8
153 169 10.5
340 343 0.9
190 201 5.8
410 423 3.2
144 155 7.6
670 689 2.8
n=7
Average % Increase in potentiation 5.9
Standard Error 1.4
Paired t-test comparing control (PK-I) and 0.0008
 potentiated currents (PK-I + a5ß1 integrin )  
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Paired t-tests were performed between the PKI and PKI+a5ß1 integrin Ab groups 
and  no significant potentiation to a5ß1 integrin activation was found in the presence of 
PKI. 
To further test if PKI blocked the potentiation of current by a5ß1 integrin 
activation, we also evaluated the significance of differences between currents potentiated 
bya5ß1 integrin Ab (Table 1) and currents potentiated by a5ß1 integrin in the presence of 
PKI (Table 3). The approach used is different from the one used in Chapter III, Sections 
A and B for evaluation of significant differences. In the present case we compared 
currents between two different groups, therefore a two-tailed t-test with unequal sample 
variance was performed. 
 
Table 4. Evaluation of significance of differences between a5ß1 integrin activated 
currents (control) and PKI + a5ß1 integrin  (potentiated currents). 
 
 a5ß1 integrin-Ab Potentiated currents PKI + a5ß1 integrin-Ab
(% increase above control current) (pA)
101.0 9.8
93.9 10.5
91.2 0.9
94.6 5.8
100.9 3.2
101.5 7.6
19.2 2.8
121.9
95.5
p-value comparing a5ß1 integrin potentiated currents and p=   0.0001
currents (Control) and PKA I + a5b1 Integrin 
(Potentiated) currents
Significance level a=0.05
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The results are tabulated in Table 4. The value of p was found to be 0.0001. Since 
p<0.05, it was concluded that there was a significant difference between the two groups, 
showing that the addition of PKI blocked potentiation of current produced by a5ß1 
integrin activation. 
 
D.  EFFECT OF PKI IN RECORDING PIPETTE ON 8-Br-cAMP 
      POTENTIATION 
The final protocol was designed to test whether 8-Br-cAMP potentiation was  
 
 
 
 
 
 
Fig. 6. Effect of the PKA phosphorylation inhibitor PKI on potentiation of cardiac 
L-type calcium channel currents by 8-Br-cAMP. Raw current traces showing the 
effect of PKI (5 µg/ml) in recording pipette on 8-Br-cAMP potentiation in HEK 293 
cells transfected with a1C, ß2a and a2-d1 subunits of the rabbit cardiac channel. 
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blocked by PKI in the recording pipette. If 8-Br-cAMP effects were inhibited solely by 
PKA, the potentiation should be completely blocked by PKI.  
PK-I (5 µg/ml) was added to the pipette solution. Control and potentiated 
currents were measured before and after the application of 8-Br-cAMP (1 mM). Raw 
traces of control and potentiated currents are shown in Fig. 6. 
 
Table 5. Summary data for effect of PKI on 8-Br-cAMP potentiation of expressed 
cardiac L-type calcium channel currents. 
 
 
 
PK I (Control)    PKI +8-Br-cAMP     % Increase in Potentiation 
(pA) (pA) above control current
139 150 7.9
89 93 4.5
169 180 6.5
115 127 10.4
230 248 7.8
520 538 3.5
236 252 6.8
n=7
Average % Increase in Potentiation 6.8
Standard Error 0.9
t-tests comparing control and potentiated groups p=0.0004
 
 
The average potentiation to 8-Br-cAMP in the presence of PKI was 6.7% in 7 
cells. Paired t-tests were performed between the PKI and PKI+8-Br-cAMP groups and it 
was found that no significant potentiation wa produced by 8-Br-cAMP in the presence of 
PKI. The data for 7 cells are tabulated in Table 5. The average potentiation in the 
presence of PKI was found to be 6.7% with a standard error of 0.9%. To further compare  
8-Br-cAMP effects in the presence and absence of PKI,  (8-Br-cAMP activated currents 
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from Table 2 and currents for PKI + 8-Br-cAMP from Table 5 were statistically tested. 
The comparisons are shown in Table 6. 
 
Table 6. Evaluation of significance of differences between 8-Br-cAMP activated 
currents (control) and PKI + 8-Br-cAMP (potentiated currents). 
 
                 8BrcAMP activation    PKI +8BrcAMP activation  
 ( % increase above control) (% increase above control) 
33.3 7.9
155.1 4.5
125.4 6.5
27.2 10.4
147.0 7.8
132.3 3.5
124.1 6.8
145.7
160.1
152.2
150.0
Average potentiation 6.8
Standard error 2.3
p-value comparing 8-Br-cAMP activated p = 0.00006
currents (Control) and PKI + 8-Br-cAMP  
 
 
 
A two-tailed t-test with sample unequal variances was performed. The p value 
was found to be 0.00006. Since p<0.05, it was concluded that there is significant 
difference  effect of PKI significantly attenuated the effects of 8-Br-cAMP. This result 
verifies that the potentiation produced by 8-Br-cAMP was mediated solely through 
PKA.
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CHAPTER IV 
                             SUMMARY AND CONCLUSIONS 
The data obtained from the experiments on potentiation of cardiac Ca2+ channel 
current by a5ß1 integrin Ab in the presence of the PKA inhibitor, PKI, are summarized in 
Fig 7. 
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Fig 7. a5ß1 integrin + PKI summary data.  Summary data (peak currents) for HEK 293 
cells transfected with a1C,  ß2a and a2-d1 subunits of the rabbit cardiac channel after 
application of a5ß1 integrin Ab alone (n=9) or a5ß1 integrin Ab during dialysis with PKI 
(n = 7). 
 
The data obtained from the experiments testing potentiation of expressed cardiac 
channels by 8-Br-cAMP and the effect of PKI inhibitor on potentiation are summarized 
in Fig 8. 
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Fig 8.  8-Br-cAMP + PKI summary data. Summary data (peak currents) for HEK 293 
cells transfected with a1C,  ß2a and a2-d1 subunits of the rabbit cardiac channel after 
application of 8-Br-cAMP  alone (n=11) or 8-Br-cAMP plus dialysis with PKI (n = 7). 
 
 
Summary data from Figures 7 and 8 show that the amount of potentiation 
produced by a5ß1 integrin activation (~190%) is roughly similar to the amount of 
potentiation produced by PKA activator 8-Br-cAMP activation (~220%). Furthermore, 
both types of potentiation were essentially (~95%) blocked in the presence of the PKA 
inhibitor PKI.  
  These findings are similar to previous work in our lab on native smooth muscle 
and the neuronal L-type calcium channels, showing that heterologously expressed 
cardiac L-type calcium channels are also potentiated by a5ß1 integrin activation. It can 
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therefore be concluded that the regulation of L-type calcium channels by a5ß1 integrin is 
a general mechanism shared by vascular smooth muscle, neuronal and cardiac channels. 
In the case of smooth muscle and neuronal L-type calcium channels, the mechanism of 
potentiation involves dual phosphorylation  
 
Rat   neuronal 1845 SEEVEYCSEP SLLSTDILSY QDDENRQLTC LEEDKREIQP SPKRSFLRSA SLGRRASFHL  
Rat     aortic 1846 ---A------ ------MF-- -E--H----- P--------- ---------- ------S---  
Rabbit cardiac 1877 G-DA-C---- -----EM--- --------AP P--E--D-RL ---KG----- ------S---  
Human  cardiac 1920 NHDT-A---- -----EM--- ---------L P-----D-RQ ----G----- ------S---  
Consensus        .e#.E.CSEP SLLST#mlSY Q#DEnRQLt. pEE#KR#Ir. sPKrgFLRSA SLGRRASFHL  
 
 
Fig 9. Sequence comparisons showing PKA phosphorylation sites. The amino acids 
marked in bold show the homologous Serine residues identified as responsible for direct 
phosphorylation of channel by PKA in various cell types. "-" indicates same sequence as 
rat neuronal channel. 
 
of the channel by both PKA and c-Src (23), whereas potentiation of the cardiac calcium 
channel appears to be mediated entirely by PKA, presumably through channel 
phosphorylation at S1928. This result is consistent with the known sequence differences 
in the C terminus of the rat neuronal, rat smooth muscle, and  rabbit cardiac channels. 
Fig. 9 shows sequence comparisons of the end of the a1C C-terminus that have been 
identified as critical for channel phosphorylation by PKA in the rat neuronal and rabbit 
smooth muscle isoforms (23). S1928 of the rabbit cardiac channel is homologous to 
S1901 of the rat neuronal cell (identified as the site responsible for direct channel 
phosphorylation by PKA). We predict that S1928 is also involved in the direct 
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phosphorylation of the cardiac channel by PKA following potentiation by a5ß1 integrin, 
since that is the only known PKA phosphorylation site on the a1 channel subunit. 
  
 .  
                                                                                                  accession# 
Rat   neuronal 2085 ILSGGAQQSP NGTLLPFVNC RDPGQDRAV* VPEDESCVYA LGRGRSEEAL PDSRSYVSNL  2144 2143  JH0427 
Rat     aortic 2089 ---------- --T------- ---------* A------AY- ---------- A---------  2148 2169  Q01815 
Rabbit cardiac 2088 ------R--- ---------R ----R---GQ NEQ-ASGAC- P-C-Q----- A-R-AG--S-  2148 2171  P15381 
Human  cardiac 2162 ------P--- --A------- --A-----G* GE--AG--R- R--AP---E- Q---V---S-  2221 2225  Q13936 
   Consensus        ILSGGA.QSP NGtLLPFVNc RDpGqDRAg  .e#DascvyA .G.g.SEEaL .DsR.yVSsL 
 
 
 
Fig. 10. Sequence comparisons showing tyrosine phosphorylation sites. The letters 
marked in bold show the homologous tyrosine residues identified as responsible for 
direct phosphorylation of channel by c-Src. "-" indicates same sequence as rat neuronal 
channel. 
 
Fig. 10 compares the amino acid sequence near the end of the of a1C C-terminus 
which has been identified as critical for c-Src induced phosphorylation of channel in  rat 
neuronal and smooth muscle cells.  Gui et al. (7) identified Y2122 (marked in bold in the 
rat neuronal sequence) as responsible for phosphorylation of the channel in that 
particular species. This site was responsible for ~50% of the potentiation produced by 
a5ß1 integrin.  Note that this residue is missing in the rabbit cardiac sequence (replaced 
by C in the rabbit cardiac sequence). The alternate sequence is most likely the reason 
that the regulation of the rabbit cardiac channel seems to be mediated completely by 
PKA phosphorylation of the channel. 
 In conclusion, my results show that the cardiac L-type calcium channel is 
potentiated by a5ß1 integrin activation and that the potentiation is mediated completely 
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by PKA, presumably involving direct channel phosphorylation at S1928 on the C-
terminus of the channels a1C subunit. 
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